Telomir Pharmaceuticals, Inc. Common Stock
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $80.5M
- Price
- $1.17
- % Change (Daily % change from the live per-ticker quote feed.)
- +8.33%
- Volume
- 100.8K
About
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Quick stats
Shares outstanding68.8M
Computed float38.4M
Float / shares55.8%
Cash runway (months)8.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001971532
Websitehttps://telomirpharma.com
AI Summary
AI-generated1/11
standardbullishclinical trial
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for its lead asset Telomir-Zn, demonstrating tumor suppression in prostate and triple-negative breast cancer (TNBC) models.
The study, published in the Journal of Oncology Research and Therapy, shows Telomir-Zn selectively targets cancer cells by depleting intracellular iron to inhibit KDM enzymes, achieving a 50-fold selectivity window over normal cells.
These findings establish the scientific foundation for the company's planned Phase 1/2 clinical trial in TNBC, for which the company holds an active IND.